Engineering fibrinogen-binding VSV-G envelope for spatially- and cell-controlled lentivirus delivery through fibrin hydrogels

Biomaterials

Volumn 32, Issue 12, 2011, Pages 3330-3339

  Padmashali, Roshan M ^a   Andreadis, Stelios T ^a,b  

^a University at Buffalo State University of New York ^*  (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Fibrin; Genetically engineered envelope; Lentivirus; Live cell array; Microarray

Indexed keywords

CLEAVAGE SITES; CROSS CONTAMINATION; DOSE-DEPENDENT MANNER; ENVELOPE GLYCOPROTEINS; FIBRIN; FIBRIN GELS; FIBRINOGEN CONCENTRATION; FLEXIBLE LINKERS; GENE DELIVERY; GENETICALLY ENGINEERED ENVELOPE; HIGH CONCENTRATION; LENTIVIRUS; LIVE CELL; MATRIX; PEPTIDE DOMAINS; SIGNAL/NOISE RATIO; SPATIAL CONTROL; TARGET CELLS; THERAPEUTIC APPLICATION; TRANSDUCTION EFFICIENCY;

GELS; GENE TRANSFER; HYDROGELS; MICROARRAYS; PEPTIDES; SYNCHROTRONS; VIRUSES;

GENE THERAPY;

BLOOD CLOTTING FACTOR 13; FIBRINOGEN; GLYCOPROTEIN; HYBRID PROTEIN; PLASMIN; PROTEINASE; UNCLASSIFIED DRUG; VIRAL ENVELOPE GLYCOPROTEIN;

ARTICLE; CONTROLLED STUDY; DIFFUSION; FLOW CYTOMETRY; GENE DELIVERY SYSTEM; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LENTIVIRINAE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN POLYMERIZATION; SIGNAL NOISE RATIO; VIRUS ENVELOPE; VIRUS GENE;

AMINO ACID SEQUENCE; ANIMALS; CATTLE; CROSS-LINKING REAGENTS; FACTOR XIII; FIBRIN; FIBRINOGEN; GENE TRANSFER TECHNIQUES; HUMANS; HYDROGELS; LENTIVIRUS; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDES; PROTEIN BINDING; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC; VIRAL ENVELOPE PROTEINS;

LENTIVIRUS; VESICULAR STOMATITIS VIRUS;

EID: 79951767973     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.01.035     Document Type: Article

References (43)

1. Shin S., Tuinstra H.M., Salvay D.M., Shea L.D. Phosphatidylserine immobilization of lentivirus for localized gene transfer. Biomaterials 2010, 31:4353-4359.
2. Ohtake N., Niikura K., Suzuki T., Nagakawa K., Sawa H., Ijiro K. Enhanced cellular uptake of virus-like particles through immobilization on a sialic acid-displaying solid surface. Bioconjug Chem 2008, 19:507-515.
3. Hu W.W., Wang Z., Hollister S.J., Krebsbach P.H. Localized viral vector delivery to enhance in situ regenerative gene therapy. Gene Ther 2007, 14:891-901.
4. Shin S., Salvay D.M., Shea L.D. Lentivirus delivery by adsorption to tissue engineering scaffolds. J Biomed Mater Res A 2010, 93:1252-1259.
5. Levy R.J., Song C., Tallapragada S., DeFelice S., Hinson J.T., Vyavahare N., et al. Localized adenovirus gene delivery using antiviral IgG complexation. Gene Ther 2001, 8:659-667.
6. Shin S., Shea L.D. Lentivirus immobilization to nanoparticles for enhanced and localized delivery from hydrogels. Mol Ther 2010, 18:700-706.
7. Bajaj B., Behshad S., Andreadis S.T. Retroviral gene transfer to human epidermal keratinocytes correlates with integrin expression and is significantly enhanced on fibronectin. Hum Gene Ther 2002, 13:1821-1831.
8. Lee H.J., Lee Y.S., Kim H.S., Kim Y.K., Kim J.H., Jeon S.H., et al. Retronectin enhances lentivirus-mediated gene delivery into hematopoietic progenitor cells. Biologicals 2009, 37:203-209.
9. Raut S.D., Lei P., Padmashali R.M., Andreadis S.T. Fibrin-mediated lentivirus gene transfer: implications for lentivirus microarrays. J Control Release 2010, 144:213-220.
10. Lugo L.M., Lei P., Andreadis S.T. Vascularization of the dermal support enhances wound reepithelialization by in situ delivery of epidermal keratinocytes. Tissue Eng Part A 2010, [Epub ahead of print], doi:10.1089/ten.tea.2010.0125.
11. Qi H., Aguiar D.J., Williams S.M., La Pean A., Pan W., Verfaillie C.M. Identification of genes responsible for osteoblast differentiation from human mesodermal progenitor cells. Proc Natl Acad Sci USA 2003, 100:3305-3310.
12. Ng F., Boucher S., Koh S., Sastry K.S., Chase L., Lakshmipathy U., et al. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 2008, 112:295-307.
13. Korchynskyi O., Dechering K.J., Sijbers A.M., Olijve W., ten Dijke P. Gene array analysis of bone morphogenetic protein type I receptor-induced osteoblast differentiation. J Bone Miner Res 2003, 18:1177-1185.
14. Beck G.R., Zerler B., Moran E. Gene array analysis of osteoblast differentiation. Cell Growth Differ 2001, 12:61-83.
15. Tian J., Andreadis S.T. Independent and high-level dual-gene expression in adult stem-progenitor cells from a single lentiviral vector. Gene Ther 2009, 16:874-884.
16. Tian J., Alimperti S., Lei P., Andreadis S.T. Lentiviral microarrays for real-time monitoring of gene expression dynamics. Lab Chip 2010, 10:1967-1975.
17. Zisch A.H., Schenk U., Schense J.C., Sakiyama-Elbert S.E., Hubbell J.A. Covalently conjugated VEGF-fibrin matrices for endothelialization. J Control Release 2001, 72:101-113.
18. Sakiyama-Elbert S.E., Panitch A., Hubbell J.A. Development of growth factor fusion proteins for cell-triggered drug delivery. FASEB J 2001, 15:1300-1302.
19. Sakiyama-Elbert S.E., Hubbell J.A. Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix. J Control Release 2000, 69:149-158.
20. Geer D.J., Swartz D.D., Andreadis S.T. Biomimetic delivery of keratinocyte growth factor upon cellular demand for accelerated wound healing in vitro and in vivo. Am J Pathol 2005, 167:1575-1586.
21. Yu J.H., Schaffer D.V. Selection of novel vesicular stomatitis virus glycoprotein variants from a peptide insertion library for enhanced purification of retroviral and lentiviral vectors. J Virol 2006, 80:3285-3292.
22. Schlehuber L.D., Rose J.K. Prediction and identification of a permissive epitope insertion site in the vesicular stomatitis virus glycoprotein. J Virol 2004, 78:5079-5087.
23. Li Y., Drone C., Sat E., Ghosh H.P. Mutational analysis of the vesicular stomatitis virus glycoprotein G for membrane fusion domains. J Virol 1993, 67:4070-4077.
24. Guibinga G.H., Hall F.L., Gordon E.M., Ruoslahti E., Friedmann T. Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype. Mol Ther 2004, 9:76-84.
25. Lei P., Padmashali R.M., Andreadis S.T. Cell-controlled and spatially arrayed gene delivery from fibrin hydrogels. Biomaterials 2009, 30:3790-3799.
26. Carr M.E., Hardin C.L. Fibrin has larger pores when formed in the presence of erythrocytes. Am J Physiol 1987, 253:H1069-H1073.
27. Herbert C.B., Nagaswami C., Bittner G.D., Hubbell J.A., Weisel J.W. Effects of fibrin micromorphology on neurite growth from dorsal root ganglia cultured in three-dimensional fibrin gels. J Biomed Mater Res 1998, 40:551-559.
28. Yang H., Joo K.I., Ziegler L., Wang P. Cell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule. Pharm Res 2009, 26:1432-1445.
29. Morizono K., Bristol G., Xie Y.M., Kung S.K., Chen I.S. Antibody-directed targeting of retroviral vectors via cell surface antigens. J Virol 2001, 75:8016-8020.
30. Lei Y., Joo K.I., Zarzar J., Wong C., Wang P. Targeting lentiviral vector to specific cell types through surface displayed single chain antibody and fusogenic molecule. Virol J 2010, 7:35.
31. Lei Y., Joo K.I., Wang P. Engineering fusogenic molecules to achieve targeted transduction of enveloped lentiviral vectors. J Biol Eng 2009, 3:8-20.
32. Dreja H., Piechaczyk M. The effects of N-terminal insertion into VSV-G of an scFv peptide. Virol J 2006, 3:69-76.
33. Szecsi J., Drury R., Josserand V., Grange M.P., Boson B., Hartl I., et al. Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA-protease interactions. Mol Ther 2006, 14:735-744.
34. Schneider R.M., Medvedovska Y., Hartl I., Voelker B., Chadwick M.P., Russell S.J., et al. Directed evolution of retroviruses activatable by tumour-associated matrix metalloproteases. Gene Ther 2003, 10:1370-1380.
35. Peng K.W., Vile R., Cosset F.L., Russell S. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther 1999, 6:1552-1557.
36. Nilson B.H., Morling F.J., Cosset F.L., Russell S.J. Targeting of retroviral vectors through protease-substrate interactions. Gene Ther 1996, 3:280-286.
37. Morizono K., Xie Y., Helguera G., Daniels T.R., Lane T.F., Penichet M.L., et al. A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide. J Gene Med 2009, 11:655-663.
38. Morizono K., Pariente N., Xie Y., Chen I.S. Redirecting lentiviral vectors by insertion of integrin-tageting peptides into envelope proteins. J Gene Med 2009, 11:549-558.
39. Gollan T.J., Green M.R. Redirecting retroviral tropism by insertion of short, nondisruptive peptide ligands into envelope. J Virol 2002, 76:3558-3563.
40. Funke S., Maisner A., Muhlebach M.D., Koehl U., Grez M., Cattaneo R., et al. Targeted cell entry of lentiviral vectors. Mol Ther 2008, 16:1427-1436.
41. Yee J.K., Friedmann T., Burns J.C. Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 1994, 43(Pt A):99-112.
42. Andreadis S.T., Roth C.M., Le Doux J.M., Morgan J.R., Yarmush M.L. Large-scale processing of recombinant retroviruses for gene therapy. Biotechnol Prog 1999, 15:1-11.
43. Bailey S.N., Ali S.M., Carpenter A.E., Higgins C.O., Sabatini D.M. Microarrays of lentiviruses for gene function screens in immortalized and primary cells. Nat Methods 2006, 3:117-122.